Yahoo · Oct 29, 2026
Could Axsome Therapeutics Turn $5,000 Into $50,000 by 2035?
The stock has experienced a pullback in the past few months.
NASDAQ · AXSM
Axsome Therapeutics, Inc.
Healthcare · Biotechnology
$144.43
Up+$0.98 (+0.68%)
Updated Nov 2, 2026, 9:38 AM
SID Score
4.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 7.5B
- P/E ratio
- -32.42
- Dividend yield
- 0.00%
- 52-week range
- $123.50 – $260.19
- Volume
- 2.17M
- Avg. volume
- 522.89K
Price performance · AXSM
AXSM price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
AXSM closed at $144.43 after 20 trading sessions, down 18.44% for the selected period.
- Last close
- $144.43
- Period change
- -18.44%
- Period low
- $142.20
- Period high
- $177.08
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $143.23 | $146.165 | $131.265 | $144.43 | 2.17M |
| Oct 29, 2026 | $146.79 | $147.4875 | $140.42 | $143.45 | 850.52K |
| Oct 28, 2026 | $141.045 | $144.14 | $140.49 | $143.51 | 739.34K |
| Oct 27, 2026 | $143.99 | $145.44 | $141.1505 | $142.20 | 1.1M |
| Oct 26, 2026 | $145.29 | $145.335 | $142.00 | $144.06 | 886.19K |
| Oct 23, 2026 | $154.66 | $154.74 | $143.90 | $145.04 | 1.59M |
| Oct 22, 2026 | $156.13 | $158.0783 | $154.2401 | $156.07 | 832.35K |
| Oct 21, 2026 | $158.83 | $160.8175 | $156.04 | $156.31 | 524.8K |
| Oct 20, 2026 | $157.65 | $164.79 | $157.375 | $159.58 | 653.89K |
| Oct 19, 2026 | $157.54 | $158.655 | $154.50 | $155.81 | 781.73K |
| Oct 16, 2026 | $160.43 | $160.43 | $156.09 | $157.14 | 873.15K |
| Oct 15, 2026 | $163.44 | $169.96 | $160.27 | $161.79 | 802.62K |
| Oct 14, 2026 | $156.44 | $164.00 | $155.1801 | $162.22 | 893.24K |
| Oct 13, 2026 | $166.01 | $166.55 | $155.685 | $156.32 | 1.33M |
| Oct 12, 2026 | $169.50 | $170.80 | $165.02 | $166.00 | 663K |
| Oct 9, 2026 | $170.18 | $170.6399 | $166.12 | $168.35 | 894.52K |
| Oct 8, 2026 | $170.09 | $172.275 | $166.21 | $170.08 | 1.07M |
| Oct 7, 2026 | $174.00 | $177.91 | $172.48 | $172.97 | 887.36K |
| Oct 6, 2026 | $176.52 | $176.52 | $169.30 | $174.34 | 1.37M |
| Oct 5, 2026 | $179.25 | $179.70 | $175.7301 | $177.08 | 858.89K |
Latest AXSM news
The latest Smart Investors Daily articles mentioning AXSM.
Stock researchCompany · Overview
Company
Market Activity
Research & News
AXSM research
Overview
Company profile and research snapshot.
Company profile
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $184.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 26, 2026 | Piper Sandler | Overweight | — |
| Oct 8, 2026 | RBC Capital | Outperform | — |
| Sep 29, 2026 | Deutsche Bank | Buy | — |
| Sep 25, 2026 | Morgan Stanley | Equal-Weight | — |
| Sep 23, 2026 | Truist Securities | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility
Axsome's steady ascent has flipped the script—it now outpaces Moderna in quarterly revenue despite starting from a fraction of its size.
Benzinga · Oct 26, 2026
Piper Sandler Maintains Overweight on Axsome Therapeutics, Lowers Price Target to $238
Piper Sandler analyst David Amsellem maintains Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and lowers the price target from $258 to $238.
Yahoo · Oct 23, 2026
2 Growth Stocks to Hold for the Next Decade (Hint: These Aren’t AI Stocks)
These drugmakers are capitalizing on their pipeline successes.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
